<HTML>
<HEAD>
</HEAD>
<BODY LINK="#0000ff" VLINK="#800080">

<B><FONT SIZE=2><P ALIGN="JUSTIFY"></P>
</FONT><FONT SIZE=5><P ALIGN="CENTER">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
</FONT>Washington, D.C. 20549</P>
<P ALIGN="CENTER"></P>
<FONT SIZE=5><P ALIGN="CENTER">FORM  8-K</P>
</FONT><P ALIGN="CENTER"></P>
<FONT SIZE=5><P ALIGN="CENTER">CURRENT REPORT</FONT><BR>
</B>__________________________________________</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="CENTER">Pursuant to Section 13 or 15 (d) of<BR>
The Securities Exchange Act of 1934</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="CENTER">December 27, 2004</B><BR>
Date of report (date of earliest event reported)</P>
<P ALIGN="CENTER"></P>
<B><U><FONT SIZE=5><P ALIGN="CENTER">&nbsp;&nbsp;&nbsp;&nbsp;FOREST LABORATORIES, INC.&nbsp;&nbsp;&nbsp;&nbsp;<BR>
</B></U></FONT>(Exact name of registrant as specified in its charter)</P>
<P ALIGN="CENTER"></P>
<P ALIGN="CENTER"><CENTER><TABLE CELLSPACING=0 BORDER=0 WIDTH=562>
<TR><TD WIDTH="44%" VALIGN="TOP">
<B><P ALIGN="CENTER">Delaware<BR>
</B><I>(State or other jurisdiction of<BR>
incorporation or organization)</I></TD>
<TD WIDTH="18%" VALIGN="TOP">
<B><P ALIGN="CENTER">1-5438<BR>
</B>(Commission<BR>
   File Number)</TD>
<TD WIDTH="38%" VALIGN="TOP">
<B><P ALIGN="CENTER">11-1798614<BR>
</B><I>(I.R.S. Employer<BR>
Identification Number)</I></TD>
</TR>
<TR><TD WIDTH="44%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="38%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="44%" VALIGN="TOP">
<B><P ALIGN="CENTER">909 Third Avenue<BR>
New York, New York <BR>
</B><I>(Address of principal executive offices)</I></TD>
<TD WIDTH="18%" VALIGN="TOP">
<P>&nbsp;</TD>
<TD WIDTH="38%" VALIGN="TOP">
<B><P ALIGN="CENTER">10022-4731<BR>
</B><I>(Zip code)</I></TD>
</TR>
</TABLE>
</CENTER></P>

<FONT SIZE=1><P ALIGN="CENTER"></P>
</FONT><B><P ALIGN="CENTER">(212) 421-7850<BR>
</B><I>(Registrant's telephone number, including area code)</I><U> <BR>
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
</U><I>(Former name or former address, if changed since last report)<BR>
</P>
<FONT SIZE=1><P ALIGN="CENTER"></P>
</FONT><P>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</P>

</I><FONT SIZE=3><P>[&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR>
[&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
[&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))<BR>
[&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<I><BR>
</P>
</I></FONT>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P>Item 8.01 <U>Other Events</P>
</U>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December 27, 2004, Forest Laboratories, Inc. ("Forest") was named as a defendant, together with Biovail Corporation, in an action brought in the United States District Court for the District of Columbia under the caption <U>Louisiana Wholesale Drug Company, Inc. and Rochester Drug Cooperative v. Biovail Corporation and Forest Laboratories, Inc.</U>  The complaint alleges attempts to monopolize under Section 2 of the Sherman Act with respect to the product Tiazac resulting from Biovail's January 2001 patent listing in the Food and Drug Administration's "Orange Book" of Approved Drug Products with Therapeutic Equivalence Evaluations.  Biovail withdrew the Orange Book listing of the patent at issue following an April 2002 Consent Order between Biovail and the Federal Trade Commission.  Biovail is the owner of the NDA covering Tiazac which Forest distributes in the United States under license from Biovail.  The action, which purports to be brought as a class action on behalf of all persons or entities who purchased Tiazac directly from Forest from February 13, 2001 to the present, seeks treble damages and related relief arising from the allegedly unlawful acts.  Forest believes there is no merit to the claims asserted against it and intends to vigorously defend this action.</P>

<P>&nbsp;</P>
<P>&nbsp;</P>
<FONT FACE="Courier,Courier New"><P ALIGN="CENTER"><A NAME="Quick_Links"></A></P>
</FONT><P ALIGN="CENTER"><A NAME="STATEMENTS_OF_INCOME"></A> SIGNATURES</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Date:  January 3, 2005</P>
<P ALIGN="JUSTIFY"><BR>
<BR>
</P><DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

<U><P>Forest Laboratories, Inc.</U><BR>
(Registrant)</P>
<P ALIGN="JUSTIFY"><BR>
</P>
<U><P>/s/ Howard Solomon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
</U>Howard Solomon,<BR>
Chairman of the Board</P>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>

<P><A NAME="STATEMENTS_OF_COMPREHENSIVE_INCOME"></A></P>

<I><P>&nbsp;</P>
</I><FONT FACE="Courier,Courier New"><P ALIGN="RIGHT">&nbsp;</P></FONT></BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "forest8k3jan05.htm", "description": "FOREST LABORATORIES, INC. 8-K JANUARY 3, 2005", "secsgml_size_bytes": 5838}]
{"company-data": {"conformed-name": "FOREST LABORATORIES INC", "cik": "0000038074", "assigned-sic": "2834", "irs-number": "111798614", "state-of-incorporation": "DE", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-05438", "film-number": "05502623"}, "business-address": {"street1": "909 THIRD AVENUE", "city": "NEW YORK", "state": "NY", "zip": "10022", "phone": "2124217850"}, "mail-address": {"street1": "909 THIRD AVENUE", "city": "NEW YORK", "state": "NY", "zip": "10022"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM  8-K
CURRENT REPORT
__________________________________________
Pursuant to Section 13 or 15 (d) of
The Securities Exchange Act of 1934
December 27, 2004
Date of report (date of earliest event reported)
FOREST LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
1-5438
(Commission
File Number)
11-1798614
(I.R.S. Employer
Identification Number)
909 Third Avenue
New York, New York
(Address of principal executive offices)
10022-4731
(Zip code)
(212) 421-7850
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01
Other Events
On December 27, 2004, Forest Laboratories, Inc. ("Forest") was named as a defendant, together with Biovail Corporation, in an action brought in the United States District Court for the District of Columbia under the caption
Louisiana Wholesale Drug Company, Inc. and Rochester Drug Cooperative v. Biovail Corporation and Forest Laboratories, Inc.
The complaint alleges attempts to monopolize under Section 2 of the Sherman Act with respect to the product Tiazac resulting from Biovail's January 2001 patent listing in the Food and Drug Administration's "Orange Book" of Approved Drug Products with Therapeutic Equivalence Evaluations.  Biovail withdrew the Orange Book listing of the patent at issue following an April 2002 Consent Order between Biovail and the Federal Trade Commission.  Biovail is the owner of the NDA covering Tiazac which Forest distributes in the United States under license from Biovail.  The action, which purports to be brought as a class action on behalf of all persons or entities who purchased Tiazac directly from Forest from February 13, 2001 to the present, seeks treble damages and related relief arising from the allegedly unlawful acts.  Forest believes there is no merit to the claims asserted against it and intends to vigorously defend this action.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date:  January 3, 2005
Forest Laboratories, Inc.
(Registrant)
/s/ Howard Solomon
Howard Solomon,
Chairman of the Board